Zobrazeno 1 - 10
of 40
pro vyhledávání: '"Steven J. Cavalier"'
Autor:
Ludwig Kappos, Till Sprenger, Nicole Mueller-Lenke, Ernst-Wilhelm Radue, Elizabeth M. Poole, Laura Gaetano, Jens Wuerfel, Steven J. Cavalier
Publikováno v:
Multiple Sclerosis (Houndmills, Basingstoke, England)
Background: Teriflunomide 14 mg significantly reduced brain volume loss (BVL) and confirmed disability worsening (CDW) compared with placebo in the TEMSO core study. Objective: To investigate the relationship between BVL from Baseline to Year 2 in th
Autor:
Antonio Bertolotto, Mark S. Freedman, Isabel Firmino, Darren P Baker, Alan Jacobs, Karthinathan Thangavelu, Tjalf Ziemssen, Aaron Boster, Nadia Daizadeh, Dana Horakova, Camms Investigators, Steven J. Cavalier, David Margolin, Elizabeth M. Poole
Publikováno v:
Multiple Sclerosis Journal-Experimental, Translational and Clinical
Background Few data exist concerning conversion to secondary progressive MS in patients treated with disease-modifying therapies. Objective Determine the proportion of alemtuzumab-treated patients converting from relapsing-remitting to secondary prog
Publikováno v:
Neurology. 83(18)
The editorial by Dr. Langer-Gould1 included misleading statements about teriflunomide. Human data for teriflunomide are available. Teriflunomide is the active metabolite of leflunomide. Animal studies demonstrated a risk of teratogenicity for both. H
Publikováno v:
Neurology. 33:254-254
Autor:
Steven J. Cavalier, Pierluigi Gambetti
Publikováno v:
Neurology. 31:714-714
Neuropathologic changes in patients with cystic fibrosis include dystrophic axons in the nucleus gracilis and demyelination of the fasciculus gracilis. We reviewed 43 autopsy cases of cystic fibrosis to determine the incidence and severity of these c
Autor:
Steven J. Cavalier, Meredith A. Weinstein, Michael T. Modic, Anthony J. Furlan, Robert E. Hobbs
Publikováno v:
Neurology. 32:280-280
Among 54 consecutive patients with acute nonseptic embolic brain infarction, there was CT evidence of hemorrhagic infarction in 1 patient (2%). None had clinical or CT evidence of massive brain hemorrhage even when anticoagulation therapy was used im
Autor:
Horáková, Dana, Boster, Aaron, Bertolotto, Antonio, Freedman, Mark S, Firmino*, Isabel, Cavalier, Steven J, Jacobs*, Alan K, Thangavelu*, Karthinathan, Daizadeh, Nadia, Poole*, Elizabeth M, Baker, Darren P, Margolin*, David H, Ziemssen, Tjalf
Publikováno v:
Multiple Sclerosis Journal - Experimental, Translational & Clinical; 12/18/2020, p1-10, 10p
Publikováno v:
Multiple Sclerosis Journal - Experimental, Translational & Clinical; 2019Supplement1, Vol. 25, p20-156, 137p
Publikováno v:
Multiple Sclerosis Journal; 2018 Supplement 1, Vol. 24, p11-117, 107p
Autor:
Horáková, Dana, Boster, Aaron, Bertolotto, Antonio, Freedman, Mark S, Firmino*, Isabel, Cavalier, Steven J, Jacobs*, Alan K, Karthinathan Thangavelu, Daizadeh, Nadia, Poole*, Elizabeth M, Baker, Darren P, Margolin*, David H, Tjalf Ziemssen
Supplemental material, sj-pdf-1-mso-10.1177_2055217320972137 for Proportion of alemtuzumab-treated patients converting from relapsing-remitting multiple sclerosis to secondary progressive multiple sclerosis over 6 years by Dana Horáková, Aaron Bost
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0b092ead60e9eae90b2a9f4b9fa69c8f